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Dialysis-related amyloidosis is a complication of long-term
chronic kidney disease (CKD) resulting in deposition of
b2-microglobulin (b2M) amyloid in osteoarticular tissue.
Clinical manifestations include destructive arthropathy, bone
cysts, and fractures. Since osteolytic lesions are prominent
findings around the b2M deposits, we sought evidence
whether b2M causes bone destruction by directly stimulating
osteoclast activity and if this was mediated by local cytokine
production. A dose-dependent increase in the number of
tartrate-resistant alkaline phosphatase-positive
multinucleated cells was found in cultured mouse marrow
cells treated with b2M. Osteoprotegerin was unable to block
this osteoclastogenic effect of b2M. Osteoblasts or stromal
cells were not necessary to induce this osteoclastogenesis, as
formation was induced by incubating b2M with colony-
forming unit granulocyte macrophages (the earliest
identified precursor of osteoclasts) or the murine RAW 264.7
monocytic cell line. b2M Upregulated tumor necrosis factor-a
(TNF-a) and IL-1 expression in a dose-dependent manner;
however, a TNF-a-neutralizing antibody blocked b2M-induced
osteoclast formation. These results show that b2M stimulates
osteoclastogenesis, supporting its direct role in causing bone
destruction in patients with CKD.
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Dialysis-related arthropathy (DRA), also referred to as b2-
microglobulin (b2M) amyloidosis, is most commonly seen in
patients with chronic kidney disease (CKD) stage 5 under-
going long-term hemodialysis therapy.1–3 However, it also
occurs among patients undergoing chronic peritoneal dialysis
and in CKD stage 4, prior to initiation of dialytic therapy.1,4
The duration of dialytic therapy is an important factor
associated with the development of DRA. Although DRA
may be observed within 3–5 years of the initiation of dialysis,
it is almost universal in patients treated by hemodialysis for
15 years or more.1,5
Dialysis-related arthropathy is characterized by amyloid
deposition mainly in bone and the surrounding joints, with
clinical presentations including carpal tunnel syndrome,
destructive arthropathy, and pathological subchondral bone
erosions and cysts.1 Deposits removed from DRA-affected
joints and peri-articular bone have demonstrated a unique
amyloid fibril protein that was found to be b2M.
2,6 Histologic
evaluation revealed the presence of both osteoclastogenesis
and active osteoclastic bone resorption on the bone surface,
with absence of osteoblastic bone formation.7
However, the pathological role of b2M as a mediator of
bone disease is not completely understood. Subcutaneous
injection of b2M induces histological evidence of bone
resorption in neonatal mice,8 and purified human b2M
induces a dose- and time-dependent net calcium efflux in
cultured murine calvariae.9,10 This calcium efflux is
mediated, in part, by interleukin-1b (IL-1b).11 b2M also
stimulates the synthesis of IL-6, a potent bone-resorbing
cytokine, leading to increase in mRNA and protein levels in
osteoblasts.12 b2M has also been shown to stimulate synovial
fibroblasts to produce stromelysin, a neutral matrix metallo-
proteinase, which is believed to be a key enzyme causing
articular destruction in inflammatory joint diseases.13 Migita
et al.14 demonstrated that b2M increases cyclooxygenase-2
protein and mRNA expression in a dose-dependent manner
from human synovial cells; however, using the mouse
calvarial resorption model, we were unable to demonstrate
any effect of b2M effect on prostaglandin E2 production.
11
Theoretically, both hormonal and local regulatory factors
can interact with b2M either as a result of direct stimulation
by b2M or by aggravating b2M effects on bone resorption.
Various studies, however, have been unable to demonstrate
an effect of parathyroid hormone (PTH) on b2M transcrip-
tion15 or an effect of 1,25-dihydroxyvitamin-D3 on b2M
immunoreactivity in osteoblast cultures.16 It has been
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demonstrated that submaximal and pharmacological con-
centrations of PTH did not augment b2M calcium efflux
from incubated calvariae cells.9 These preliminary data
suggest that b2M does not interact with calciotropic
hormones.9,15,16
Cytokines, including IL-1, IL-6, and tumor necrosis factor
(TNF), have known stimulatory effects on cell-mediated
bone resorption.17,18 The bone-resorbing effects of b2M may
be mediated by interaction with cytokines. Thus, the purpose
of this study was to evaluate whether b2M can directly
stimulate osteoclastogenesis and osteoclastic bone resorption.
RESULTS
Calvariae from neonatal mice were incubated for 48 h in
either control medium, medium supplemented with b2M
(108–106 M), or PTH (108 M), and calcium flux was
determined (Figure 1). Compared wit the control, the
presence of b2M at concentrations of 10
8 to 106 M resulted
in a dose-dependent increase in calcium efflux from bone. At
a b2M concentration of 10
5
M, the calcium efflux was similar
to that observed with PTH (b2M¼ 427±48;
PTH¼ 487±39.5 nmol per bone per 48 h). These data are
comparable to those observed previously.9,19
Net calcium release from bone results either from
increased bone resorption or decreased bone formation. To
evaluate the role of b2M in inducing bone resorption, the
effect of b2M on the induction of osteoclast formation was
evaluated. RAW 264.7 cells (106 ml1) were incubated with
b2M. After 6 days of culture, tartrate-resistant acid
phosphatase staining-positive (TRAPþ ) multinucleated cells
could be clearly identified as mature osteoclasts under light
microscopy (Figure 2a). b2M Caused a dose-related increase
in osteoclast formation (Figure 2b). To further verify the
osteoclastic nature of the cells, they were also characterized by
examining specific markers of osteoclastic expression, such as
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Figure 1 | b2M-Induced calcium efflux from neonatal calvariae.
Neonatal mouse calvariae were incubated in either control
medium or with b2M (10
8–106 M), or PTH (108 M) for 48 h and
calcium flux was determined. b2M Caused a dose-dependent
increase in calcium efflux. Data are expressed as mean±s.e.m. *,
greater than control; þ , greater than 108 M.
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Figure 2 | b2M Induces osteoclast formation. Light microscopy of RAW 264.7 cells (2000 cells/well), which were incubated in either control
medium or with b2M (10
5
M), or 105 M of an amyloid fragment (AA 1–41), for 6 days. TRAPþ multinucleated cells can be seen in incubation
with b2M, but not with control medium or medium supplemented with the amyloid fragment. b2M Induced a dose-dependent increase in
osteoclast formation. Data are expressed as mean±s.e.m. *, greater than control; þ , greater than 107 M.
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TRAP, b3-integrin, and the calcitonin receptor (Figure 3). To
determine the specificity of b2M in inducing osteoclastogen-
esis, cells were also incubated with amyloid protein fragment
(aa 1–41), which failed to induce osteoclast formation (Figure
2a) and induction of osteoclastic gene expression (Figure 3)
in concentrations up to 105 M. In addition, osteoclastic-
resorptive activity was confirmed by plating cells on a
synthetic mineralized matrix. Pit formation could be
visualized clearly by microscopy following cell removal
(Figure 4).
The effect of b2M on the production of the osteoclasto-
genic factors IL-1b, and TNF-a expression, was determined
by reverse transcriptase-polymerase chain reaction (RT-PCR)
using specific primers for both cytokines on RNA isolated
from bone marrow cells treated with b2M. As shown in
Figure 5, b2M stimulated the expression of both IL-1b and
TNF-a. RT-PCR analyses clearly demonstrated the induction
of the expression of these proinflammatory cytokines. This
induction was noted at 6 h and reached maximum at 24 h for
TNF-a and 48 h for IL-1b. The reduction of TNF-a
expression at 48 h could be related to the loss of b2M
bioactivity, since b2M was added only at the beginning of the
incubation period. However, the increased amount of IL1b at
48 h could be related to the effect of secreted TNF-a in
response to b2M, which could subsequently stimulate IL1b
expression. It has been well demonstrated that TNF-a
induces IL-1b expression. This effect is specific as no
stimulation was noted in control cells where osteoclast
precursors were treated with vehicle for 48 h.
However, the effect of b2M on stimulating osteoclastogen-
esis appeared to be independent of RANK/RANKL activa-
tion. Increasing concentrations of osteoprotegerin had no
effect on inhibiting osteoclast formation in bone marrow
cells incubated with 105 M b2M, as opposed to the inhibition
noted in the cells incubated with RANKL (50 ng ml1)
and macrophage colony-stimulating factor (25 ng ml1)
(Figure 6). Although both IL-1b and TNF-a expression
were increased by b2M, it appears that only
TNF-a is involved in b2M-induced osteoclastogenesis as
co-incubation of 105 M b2M with increasing concentrations
of TNF-a-neutralizing antibody resulted in a dose-dependent
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Figure 3 | b2M Induces TRAP, b3-integrin, and calcitonin-
receptor gene expression in osteoclast precursor cells. 105 M
b2M, but not control medium or 10
5
M amyloid fragment,
induced gene expression for TRAP, b3-integrin, and the calcitonin
receptor in osteoclast precursor cells. mRNA was extracted
following 6 days of culture (formation of mature osteoclast).
Glyceraldehyde-3-phosphate dehydrogenase served as a
housekeeping gene.
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Figure 4 | b2M Induces osteoclastic bone resorption.
Osteoclastic bone-resorptive activity was determined by
formation of resorption pits on calcium phosphate membranes.
RAW 264.7 cells were plated on a synthetic calcium phosphate
mineralized matrix and incubated for 2 weeks with and without
b2M. Pit formation could clearly be observed in the b2M-treated
cultures and were not observed in the vehicle-treated cells.
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Figure 5 | b2M Induces cytokine expression in osteoclast
precursors. Expression of the osteoclastogenic cytokines, IL-1b,
and TNF-a, was determined by semi-quantitative RT-PCR using
specific primers for both cytokines on RNA isolated from bone
marrow cells treated with b2M. b2M Stimulated the expression of
both IL-1b and TNF-a. Control incubations were only performed
for 48 h. Glyceraldehyde-3-phosphate dehydrogenase served as a
housekeeping gene.
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inhibition of osteoclastogenesis (Figure 7). In contrast, co-
incubation with increasing concentrations of the neutralizing
antibody against IL-1b had no effect on b2M-induced
osteoclastogenesis (Figure 7).
DISCUSSION
b2-Microglobulin is the light-chain component of the major
histocompatibility complex class I molecule. It is synthesized
by all cells that express major histocompatibility complex
class I and covalently associates with the heavy chain at the
cell surface.20 When the major histocompatibility complex is
shed from the surface, b2M dissociates from the heavy chain
and enters the circulation as a monomer with a molecular
weight of approximately 12 000 Da. In patients with normal
kidney function, b2M is freely filtered by the glomerulus and
then reabsorbed and catabolized by proximal tubular cells.21
However, in patients with CKD, there is significant
accumulation of b2M resulting in significant tissue deposi-
tion.22–24 There appears to be a predilection for b2M
deposition into osteoarticular areas, where a characteristic
amyloidosis develops with clinical presentations including
carpal tunnel syndrome, destructive arthropathy, and patho-
logical subchondral bone erosions and cysts.1,24 Thus, it
appears that b2M has a direct pathologic effect on bone
resulting in boney destruction.
The pathophysiological effects of b2M on bone remodeling
have been difficult to unravel. Histologic evaluation of
affected areas demonstrated the presence of both osteoclas-
togenesis and active osteoclastic bone resorption on the bone
surface.7 The lesions progress to the development of cysts,
which are comprised of the b2M amyloid.
23 The pathology
appears to be specific to the osteoclast, as there is an absence
of osteoblastic bone formation.7 The subcutaneous injection
of b2M induces histological evidence of bone resorption in
neonatal mice,8 and purified human b2M induces a dose- and
time-dependent net calcium efflux in cultured murine
calvariae (Figure 1; Moe and Sprague9 and Moe et al.10).
This calcium efflux has been shown to be mediated, in part,
by IL-1b.11 b2M Also stimulates the synthesis of IL-6, a
potent bone-resorbing cytokine, leading to an increase in
mRNA and protein levels in osteoblasts.12 Other studies have
demonstrated that b2M can stimulate synovial fibroblasts to
produce stromelysin, a neutral matrix metalloproteinase,
which is believed to be a key enzyme causing articular
destruction in inflammatory joint diseases.13 The findings
that b2M induces the synthesis of collagenase-1 from rabbit
synovial fibroblasts and the preferential collagen binding
capacity of b2M also supports the hypothesis that b2M has a
principal role in modulating connective tissue break-
down.25,26 Migita et al.14 demonstrated that b2M increases
cyclooxygenase-2 protein and mRNA expression in a dose-
dependent manner from human synovial cells; however,
using the mouse calvarial resorption model, we were unable
to demonstrate an effect of b2M effect on prostaglandin E2
production.11
This study demonstrates the ability of b2M to induce the
formation of osteoclasts, which are capable of resorbing bone
(Figures 2 and 4). Theoretically, both hormonal and local
regulatory factors can interact with b2M either as a result of
direct stimulation by b2M or by aggravating b2M effects on
bone resorption. Various studies, however, have been unable
to demonstrate an effect of PTH on b2M transcription,
15 or
an effect of 1,25-dihydroxyvitamin-D3 on b2M immunor-
eactivity in osteoblast cultures.16 It has been demonstrated
0
20
40
60
80
100
120
Osteoprotegerin (ng ml–1)
∗
∗
∗
N
o.
 o
f o
st
eo
cla
st
s 
pe
r w
el
l
RANKL (50 ng ml–1), 
M-CFS (25 ng ml–1) β2M (10
–5 M)
500501010
Figure 6 | Role of the RANK/RANKL pathway in b2M-induced
osteoclast formation. Bone marrow cells were incubated with
either b2M or RANKL (50 ng ml
1), and macrophage colony-
stimulating factor (25 ng ml1), for 6 days. Osteoprotegerin, a
RANKL decoy, was added at increasing concentrations and the
effect on osteoclast formation was determined. Osteoprotegerin
inhibited RANKL/macrophage colony-stimulating factor induced
osteoclast formation, but had no effect on osteoclast formation
induced by b2M. Data are expressed as mean±s.e.m. *, different
from b2M.
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Figure 7 | Inhibition of b2M-induced osteoclastogenesis by
TNF-a-neutralizing antibody. Bone marrow cells were incubated
with b2M and co-incubated with increasing concentrations of
neutralizing antibody against either TNF-a or IL-1b. The addition
of neutralizing antibody against TNF-a resulted in a
dose-dependent inhibition of osteoclastogenesis. In contrast,
co-incubation with increasing concentrations of neutralizing
antibody against IL-1b had no effect on the b2M-induced
osteoclastogenesis. Data are expressed as mean±s.e.m. *,
different from IL-1b.
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that submaximal and pharmacological concentrations of
PTH did not augment b2M calcium efflux from incubated
calvariae cells.9 These data suggest that b2M does not interact
with calciotropic hormones.9,15,16
The mechanism by which b2M can induce osteoclast
formation appears to be rather complex and has yet
to be fully elucidated. These studies suggest that the
b2M-induced osteoclastogenesis is mediated independently
of stimulation of the RANK/RANKL pathway. Using
the RANKL decoy receptor, osteoprotegerin, had no effect
on blocking osteoclast formation in RAW 264.7 cells
incubated with b2M. Cytokines, including IL-1, IL-6, and
TNF-a, have known stimulatory effects on cell-mediated
bone resorption.17,18 In fact, we have previously
demonstrated that b2M-induced calcium efflux from neona-
tal mouse calvariae can be completely blocked by
co-incubation with IL-1b antibody.11 This study further
demonstrated that b2M increases the expression of both
IL-1b and TNF-a, potent stimulators of osteoclastogenesis.
However, blocking the action of IL-1b by co-incubation
with a specific neutralizing antibody to IL-1b did not
alter the osteoclastogenic effect of b2M (Figure 7). In
contrast, co-incubating cells with increasing concentrations
of a neutralizing antibody against TNF-a resulted in a dose-
dependent inhibition of b2M-induced osteoclastogenesis.
TNF-a has been demonstrated to promote osteoclastogen-
esis, particularly in states of inflammatory osteolysis, such as
rheumatoid arthritis.27 This could be explained by the
differential roles of IL-1 and TNF-a. TNF-a is important
for the induction of differentiation of osteoclasts, whereas IL-
1, in conjunction with TNF-a, induces osteoclastic bone
resorption.28
Furthermore, b2M increases in osteoclastogenic cytokines
may facilitate bone resorption and predispose osteoarticular
structures to deposition of b2M amyloid. This result is
consistent with the observation that b2M-induced calcium
release from neonatal calvariae can be prevented completely
by IL-1b antibody.11 Both hormonal and local regulatory
factors participate in a complex regulation of bone
mineralization and b2M may act via any of these pathways.
In summary, the exact pathogenesis of b2M as a mediator
of bone disease is unknown. Dialysis-related amyloidosis is
typically seen among long-term chronic hemodialysis
patients. The increased duration of dialytic therapy directly
correlates with the incidence of b2M-amyloid accumulation
in osteoarticular tissue. These studies demonstrate that
b2M has the ability to directly increase osteoclast-induced
bone resorption. Inflammatory local bone destruction
precipitates the migration of further inflammatory cells,
and the ensuing release of more cytokines, leading to further
tissue destruction. Local bone resorption and surrounding
tissue become the site for continued deposition of b2M
deposition and amyloid formation. Clearly, more work is
required to further elucidate the relationship between the
accumulation for b2M and evolution of progressive tissue
destruction.
MATERIALS AND METHODS
All animal procedures were conducted in accordance with the NIH
Guide for the Care and Use of Laboratory Animals and the IACUC
guidelines at Evanston Northwestern Healthcare.
Organ culture of bone
Calvariae of 5- to 7-day-old CD-1 Swiss mice were removed and
cultured as described previously.10–12,29,30 Following dissection,
calvariae were preincubated in Dulbecco’s modified Eagle’s medium
supplemented with 15% horse serum, 2.8 mM L-glutamine,
50 IU ml1 potassium penicillin, 50 mg ml1 streptomycin (Gibco
BRL, Gaithersburg, MD, USA) for 18 h at 37 1C for equilibration
and removal of cytokines released during dissection. Pairs of
calvariae were then placed in 35-mm Petri dishes containing 2 ml of
the above medium, with the appropriate treatment or vehicle, which
had been preincubated for 1 h for equilibration. Bone cultures were
then incubated in control or experimental media for 48 h and
aliquots of medium obtained for subsequent analysis. The calvariae
were incubated in the appropriate experimental (either purified
human b2M; Cortex Biochem Inc., San Leandro, CA, USA; or
bovine parathyroid hormone PTH 1-34; Bachem, Torrance, CA,
USA) or control media. All incubations were performed in
quadruplicate. The purity of the human b2M was previously
established by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis analysis.12
Calcium measurements
Calcium concentration of the culture medium before and after the
incubation period was determined by automated fluorometric
titration analysis (Calcette; Precision Systems, Sudbury, MA, USA)
as described previously.10–12,29,30 Net calcium flux was calculated
using the following equation: Jca¼Vm (CfCi), where Vm is the
medium volume (2 ml) and Cf and Ci are the final and initial
calcium concentrations, respectively, in nanomoles per bone per
incubation time. A positive flux (efflux) indicates movement of
calcium from bones into the medium, and negative flux (influx)
movement from the medium to bone.
Effect of b2M on osteoclast formation
Long bone from 4- to 5-week old balb-c/3 mice were isolated
following killing. Bone marrow was isolated under sterile
condition using 20% FCS-alpha MEM media. Following 1 h of
incubation at 37 1C, non-adherent bone marrow cells were
collected and thereafter incubated (106 ml1) with different
concentrations of b2M for osteoclast assay. After 6 days of culture,
cells were fixed in 3% formaldehyde and stained for TRAP activity,
which represents osteoclast activity. Osteoclast formation was
evaluated by counting TRAP (þ ) multinucleated cells. Mature
osteoclasts were also characterized by examining specific marker of
expression, such as TRAP, b3-integrin, and calcitonin receptor.
mRNA was extracted from osteoclast precursors that had been
exposed to b2M, buffer, or the amyloid fragment 1–41 (Sigma, St
Louis, MO, USA) as a negative control. RT-PCR was performed
using specific primers for TRAP, calcitonin receptor, and b3-
integrin. Glyceraldehyde-3-phosphate dehydrogenase mRNA ex-
pression was used as a housekeeping gene to monitor overall
expression and mRNA integrity. The reverse transcription was
performed using random hexamers at 42 1C for 15 min, followed
by 5 min at 95 1C and 5 min at 5 1C. Five microliters of the reverse
transcription reaction were used for PCR, which was performed as
follows: 95 1C (30 s) for denaturation, 58 1C (30 s) for annealing,
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and 72 1C for extension (30 s) for 35 cycles. This was followed by
5 min of final extension at 72 1C. PCR products were sized in 2%
agarose gels and viewed under UV light.
Finally, osteoclast bone-resorptive activity was assessed by
incubating osteoclast precursors with and without b2M on a
synthetic calcium phosphate mineralized matrix (BD Biosciences,
San Jose, CA, USA) for 2 weeks. Pit formation was visualized by
optical microscopy after cell removal.
To examine whether b2M acts directly on osteoclast precursors,
colony-forming unit-granulocyte macrophage, which represent the
earliest identified precursor for osteoclasts, were used as previously
described.31 Bone marrow cells were cultured in methylcellulose
in the presence of 2 ng ml1 of granulocyte–macrophage colony-
stimulating factor for 6 days, and colony-forming unit-granulocyte
macrophage colonies were isolated using inverted microscopy,
washed, and used for osteoclast assay as detailed in legends to
figures.
To rule out possible contamination by stromal cells, the RAW
264.7 cell line was also used as a source of pure osteoclast precursors.
RAW 264.7 cells are a murine monocyte cell line with features of
osteoclast precursors. Upon appropriate stimulation, they differ-
entiate to form mature osteoclast. RAW 264.7 cells are widely used
as osteoclast precursors, especially for examining Factors that act
directly on osteoclast precursors.32 For conditions of treatment,
please see figure legends.
Effect of b2M on IL-1 and TNF-a expression
To examine the capacity of b2M to induce cytokines expression,
total RNA from osteoclast precursors induced by b2M at different
time were isolated using Trizol and following the manufacturer’s
guidelines (Invitrogen, Carlsbad, CA, USA). The effect of b2M on
TNF-a and IL-1 was evaluated by RT-PCR using specific primers
TNF-a (forward 50-accatgagcacagaaagcatg-30, reverse 50-gccccctcag
gggtgtccttg-30) and IL-1 (sense 50-ctttgaagttgacggacccc-30, rev.
50-ggcccaaggccacaggtatt-30). Briefly, following reverse transcription
using Mulo-Reverse transcriptase (Perkin Elmer, Boston, MA, USA),
2 ml of the reaction were used for PCR reaction at 60 1C as the
annealing temperature and 72 1C for extension for 30 cycles.
Glyceraldehyde-3-phosphate dehydrogenase was used to monitor
equal RNA content.
Role of the RANK/RANK ligand axis
The RANK/RANKL axis has been described to mediate the effect of
major osteotropic factors on osteoclast biology.27 The induction of
RANKL expression by accessory cells (osteoblast/stromal cells) is
necessary for the formation of mature osteoclast. This effect is
blocked by osteoprotegrin, which is a decoy receptor of RANKL. The
expression level of these two factors dictates bone-remodeling status.
However, some factors such as proinflammatory cytokines, TNF-a,
and IL-1 are able to bypass to some extent the role of RANK/
RANKL.28 Therefore, in order to examine whether RANKL mediates
the osteoclastogenic capacity of b2M, we incubated mononuclear
bone marrow cells with 105 M of b2M in the presence or absence of
increasing concentrations of osteoprotegrin. Osteoclast formation
was examined after 6 days of stimulation as described above. To
further evaluate the role of TNF-a and IL-1 in mediating
osteoclastogenesis, we incubated mononuclear bone marrow cells
with 105 M of b2M in the presence or absence of increasing
concentrations of neutralizing antibody against either IL-1b or
TNF-a. Osteoclast formation was examined after 6 days of
stimulation as described previously.
Statistical analysis
Tests for significance of differences between group means were
performed using a t-test when only two groups were involved, and
with analysis of variance with a post priori multiple comparison if
more than two groups were involved. All calculations were
performed using the statistical analysis package SYSTAT (Evanston,
IL, USA). A P-value less than 0.05 was considered significant.
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